Steve Chapman ’02 led Natera in ringing the NASDAQ opening bell to commemorate the biotechnology company’s 10-year anniversary as a publicly traded entity in July 2025.

A leading authority on the commercialization of genetic testing, Chapman is Natera’s chief executive officer and serves on its board of directors. Under his leadership, Natera has launched 20 products that have transformed patient care, including two of the fastest growing genetic tests of all time.

Chapman earned his bachelor’s degree in microbiology, immunology, and molecular genetics, graduating with honors. He began his career as a researcher in the department of human genetics at the UCLA, where he designed arrays identifying SNPs associated with multiple sclerosis. Before his appointment as CEO in 2019, Chapman held a number of other leadership positions at Natera, including chief operating officer. Earlier in his career, he worked at Genzyme Genetics.

Chapman, who has authored multiple scientific papers, serves on the board of directors of the American Clinical Laboratories Association (ACLA) and the Coalition for 21st Century Medicine. In 2024 and 2025, he was named one of the top healthcare technology CEOs by Healthcare Technology Report and was named BioTechnology Innovator of the Year by BioTech Breakthrough in 2024. He has been a guest on influential shows and podcasts, including CNBC’s Squawk Box and Vanguards of Healthcare by Bloomberg Intelligence, and featured in The Wall Street Journal and other outlets.

Natera’s suite of products includes the Signatera™ oncology test for molecular residual disease, the Prospera™ transplant assessment test, the Renasight™ kidney gene panel which screens for genetic causes of chronic kidney disease and the highly differentiated Panorama™ test serving patients in the non-invasive prenatal testing market.

Read Chapman’s previous class note here.